Management's discussion and analysis of financial condition and results of operations highlights the importance of mobilizing and deploying IT-based resources in combination with leveraging the value of other resources and capabilities. The firm’s IT capabilities represent the application of physical or intangible IT resources such as technology, knowledge, practices, relationships, management skills, and business process understanding to further organizational goals. The evolution in the operating model focuses on maintaining a disciplined approach in marketing, selling, and administrative expenses, which enables the delivery of necessary strategic, financial, and operational flexibility to invest in the highest priority opportunities within the portfolio. The integration of information technology infrastructure has streamlined the company's pricing and information technology systems, enhancing operational efficiency and supporting business innovation. The firm continues to advance and invest in its cell therapy portfolio, reflecting a commitment to innovation and the development of transformational medicines. The strategic management practices employed are designed to drive long-term business value, integrating environmental, social, and governance (ESG) strategies into the core business strategy, which addresses the opportunities and potential impacts of ESG issues directly connected to the business. The firm’s strategy combines the resources, scale, and capability of a large pharmaceutical company with the speed, agility, and focus on innovation typically found in the biotech industry. The focus on discovering, developing, and delivering innovative medicines is supported by significant investments in research and development, which includes the allocation of strategic resources to enhance IT capabilities. The firm’s operational flexibility is further demonstrated through its commitment to maintaining a strong investment-grade credit rating and returning capital to shareholders, while also evaluating the impact of legislative changes on its operations. The company’s ability to adapt to market dynamics and external influences is crucial for sustaining competitive advantage, particularly in light of increasing pressures from pharmaceutical market access and pricing controls. The firm’s IT governance framework supports the management of information reliability, security, and confidentiality, ensuring that data management practices align with changing business needs and directions. The integration of digital technologies into the operational framework facilitates enhanced connectivity and supports the firm's capability to respond to market demands effectively. The ongoing evaluation of capital expenditures related to the expansion of manufacturing capabilities reflects a strategic resource allocation aimed at optimizing operational performance and ensuring compliance with regulatory contexts. The firm’s commitment to innovation partnerships and the development of a robust technology portfolio are essential for maintaining market agility and addressing the evolving needs of consumers. Overall, the firm’s IT capabilities are integral to its strategic decision-making processes and organizational effectiveness, enabling it to navigate the complexities of the biopharmaceutical landscape while driving performance improvements and value creation.